Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 3644Carcinoma, Non-Small-Cell Lung 3585Small Cell Lung Carcinoma 576Breast Neoplasms 419Neoplasms 299Adenocarcinoma of Lung 249Colorectal Neoplasms 222Melanoma 201Mesothelioma, Malignant 183Pancreatic Neoplasms 179Prostatic Neoplasms 178Brain Neoplasms 178Head and Neck Neoplasms 173Neoplasm Metastasis 167Ovarian Neoplasms 153Esophageal Neoplasms 152Mesothelioma 145Colonic Neoplasms 140Stomach Neoplasms 139NSCLC 115Pleural Effusion, Malignant 114Carcinoma, Renal Cell 109Urinary Bladder Neoplasms 105Disease 96Sarcoma 85Uterine Cervical Neoplasms 82Thymoma 79Liver Neoplasms 77Motor Activity 75Squamous Cell Carcinoma of Head and Neck 72

Interventions

Pemetrexed 1Injections, Subcutaneous 1Infusions, Intravenous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer × Thoracic × Clear all
NCT06505837 2025-08-28

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer(NSCLC)

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Active not recruiting
395 enrolled
Thoracic

Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡